Clinical Trial Update: Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria [Phase 3]

View source ↗

Summary

Phase 3 trial exploring golimumab for inducing clinical remission in early peripheral spondyloarthritis (ASAS criteria); study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Spondyloarthritis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Peripheral Spondylarthritis | Phase 3 | Status: COMPLETED